Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968755 · ClinicalTrials.gov registry record · NA
Leveraging Chatbot to Improve PrEP in the Southern United States
A NA study, sponsored by Yale University.
- Not yet
- Registry status
- NA
- Development phase
- 145
- Enrollment target
NCT05968755: Clinical Trial NA study, sponsored by Yale University.
NCT05968755 is a NA study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 145 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05968755, a NA study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 145 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a chatbot intervention to promote PrEP awareness and uptake among Black men who have sex with men (MSM) in the Southern United States.
Primary Outcome
PrEP awareness will be measured as the proportion of participants who are aware of PrEP. Specifically, the investigators will collect PrEP awareness by asking participants standardized questions through a Qualtrics survey.
Interventions
- DEVICE A chatbot designed to promote PrEP awareness and uptake for Black MSM
- OTHER General educational messages
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2027-07-01 |
| Phase | NA |
What is known before NCT05968755 opens enrollment
NCT05968755 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which A chatbot designed to promote PrEP awareness and uptake for Black MSM is the first listed.
NCT05968755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05968755 about?
NCT05968755 is a clinical study titled "Leveraging Chatbot to Improve PrEP in the Southern United States". The purpose of this study is to develop a chatbot intervention to promote PrEP awareness and uptake among Black men who have sex with men (MSM) in the Southern United States.
What is the current status of trial NCT05968755?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 145 participants. The study started on 2026-07-20. Estimated completion is 2027-07-01.
What interventions are being tested in trial NCT05968755?
The interventions under investigation include: A chatbot designed to promote PrEP awareness and uptake for Black MSM (DEVICE), General educational messages (OTHER).
Who is sponsoring clinical trial NCT05968755?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05968755's enrollment target sits among peer trials
145 705th of 2000 higher than 1,295 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI